Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH)

NCT00710827 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00710827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00710827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH)
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Withdrawn
Start date
October 31, 2008
Completion date
October 31, 2008
Enrollment
0 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadism